On September 3, HBM HOLDINGS-B rose 5.21% in regular trading, trading at 15.13 HKD/share, with turnover of HKD 123 million, extending the prior session's rebound momentum.
On the news front, the company recently reported H1 interim results showing revenue of USD 122 million, up 20.9% year-over-year, with molecule licensing and collaboration revenue rising from USD 93.7 million to USD 113 million. CICC noted the results exceeded expectations, primarily driven by CTLA-4 overseas licensing income, highlighting continued business development that validates the company's platform value. However, the brokerage also flagged that collaboration revenue still accounts for over 90% of total income, and earnings may fluctuate with deal timing and revenue recognition cadence.
Additionally, the company will be formally included in the Hang Seng Composite Index effective September 7, after which its shares are expected to meet eligibility criteria for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect trading. The approaching inclusion date has fueled expectations of incremental capital inflows, which, combined with oversold rebound demand following consecutive prior declines, jointly supported the stock's upward movement.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments